Figure 3.
Forest plot of summary odds ratios for sICH comparing patients with bridging therapy, MT and added IAF to patients with direct MT and added IAF. *For Anadani et al we used PH2 as sICH surrogate. IAF, intra-arterial fibrinolytics; IVT, intravenous thrombolysis; MT, mechanical thrombectomy; PH2, parenchymal hematoma type 2; sICH, symptomatic intracranial hemorrhage; tPA, tissue plasminogen activator; uPA, urokinase.